7 results on '"Kunka Mohanram Ramkumar"'
Search Results
2. The pivotal role of Nrf2 activators in adipocyte biology
- Author
-
Goutham V. Ganesh, A.S. Annie-Mathew, Kunka Mohanram Ramkumar, Subramanian Prem-Santhosh, D. V. L. Sarada, and Ravichandran Jayasuriya
- Subjects
Pharmacology ,Adipogenesis ,Kelch-Like ECH-Associated Protein 1 ,NF-E2-Related Factor 2 ,Adipose tissue ,Biology ,medicine.disease ,medicine.disease_cause ,Cell biology ,chemistry.chemical_compound ,Insulin resistance ,chemistry ,Adipose Tissue ,Adipocyte ,Lipogenesis ,Nonalcoholic fatty liver disease ,medicine ,Adipocytes ,Lipolysis ,Animals ,Humans ,Obesity ,Reactive Oxygen Species ,Oxidative stress - Abstract
Adipose tissue is instrumental in maintaining metabolic homeostasis by regulating energy storage in the form of triglycerides. In the case of over-nutrition, adipocytes favorably regulate lipogenesis over lipolysis and accumulate excess triglycerides, resulting in increased adipose tissue mass. An abnormal increase in hypertrophic adipocytes is associated with chronic complications such as insulin resistance, obesity, diabetes, atherosclerosis and nonalcoholic fatty liver disease. Experimental studies indicate the occurrence of oxidative stress in the pathogenesis of obesity. A common underlying link between increasing adipose tissue mass and oxidative stress is the Nuclear Factor Erythroid 2-related factor 2 (Nrf2), Keap1-Nrf2-ARE signaling, which plays an indispensable role in metabolic homeostasis by regulating oxidative and inflammatory responses. Additionally, Nrf2 also activates CCAAT/enhancer-binding protein α, (C/EBP-α), C/EBP-β and peroxisome proliferator-activated receptor γ (PPARγ) the crucial pro-adipogenic factors that promote de novo adipogenesis. Hence, at the forefront of research is the quest for prospecting novel compounds to modulate Nrf2 activity in the context of adipogenesis and obesity. This review summarizes the molecular mechanism behind the activation of the Keap1-Nrf2-ARE signaling network and the role of Nrf2 activators in adipocyte pathophysiology.
- Published
- 2021
3. Unraveling the role of ER stress inhibitors in the context of metabolic diseases
- Author
-
Dornadula Sireesh, Kunka Mohanram Ramkumar, and Chodisetty Sarvani
- Subjects
0301 basic medicine ,XBP1 ,Context (language use) ,Protein Serine-Threonine Kinases ,Endoplasmic-reticulum-associated protein degradation ,Endoplasmic Reticulum ,Small Molecule Libraries ,eIF-2 Kinase ,03 medical and health sciences ,Metabolic Diseases ,Drug Discovery ,Endoribonucleases ,Animals ,Humans ,Medicine ,Protein Kinase Inhibitors ,Pharmacology ,ATF6 ,business.industry ,Endoplasmic Reticulum Stress ,In vitro ,Activating Transcription Factor 6 ,Cell biology ,Enzyme Activation ,030104 developmental biology ,Apoptosis ,Immunology ,Unfolded Protein Response ,Unfolded protein response ,business ,Homeostasis - Abstract
ER stress is provoked by the accumulation of unfolded and misfolded proteins in the ER lumen leading to perturbations in ER homeostasis. ER stress activates a signaling cascade called the Unfolded Protein Response (UPR) which triggers a set of transcriptional and translational events that restore ER homeostasis, promoting cell survival and adaptation. If this adaptive response fails, a terminal UPR program commits such cells to apoptosis. Existing preclinical and clinical evidence testify that prolonged ER stress escalates the risk of several metabolic disorders including diabetes, obesity and dyslipidemia. There have been considerable efforts to develop small molecules that are capable of ameliorating ER stress. Few naturally occurring and synthetic molecules have already been demonstrated for their efficacy in abrogating ER stress in both in vitro and in vivo models of metabolic disorders. This review provides a broad overview of the molecular mechanisms of inhibition of ER stress and its association with various metabolic diseases.
- Published
- 2017
- Full Text
- View/download PDF
4. The pivotal role of nuclear factor erythroid 2-related factor 2 in diabetes-induced endothelial dysfunction
- Author
-
Ravichandran Jayasuriya, Amin Karan, D. V. L. Sarada, Kunka Mohanram Ramkumar, and Elango Bhakkiyalakshmi
- Subjects
0301 basic medicine ,NF-E2-Related Factor 2 ,Vasodilation ,Inflammation ,medicine.disease_cause ,Antioxidants ,Nitric oxide ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Transcriptional regulation ,Medicine ,Humans ,Endothelial dysfunction ,Pharmacology ,business.industry ,Type 2 Diabetes Mellitus ,medicine.disease ,KEAP1 ,Oxidative Stress ,030104 developmental biology ,chemistry ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,Cancer research ,Endothelium, Vascular ,medicine.symptom ,business ,Oxidative stress ,Diabetic Angiopathies - Abstract
Endothelial dysfunction (ED) is a key event in the onset and progression of vascular complications associated with diabetes. Regulation of endothelial function and the underlying signaling mechanisms in the progression of diabetes-induced vascular complications have been well established. Recent studies indicate that increased oxidative stress is an important determinant of endothelial injury and patients with hypertension display ED mediated by impaired Nitric Oxide (NO) availability. Further, oxidative stress is known to be associated with inflammation and ED in vascular remodeling and diabetes-associated hypertension. Numerous strategies have been developed to improve the function of endothelial cells and increasing number of evidences highlight the indispensable role of antioxidants in modulation of endothelium-dependent vasodilation responses. Nuclear factor Erythroid 2-related factor 2 (Nrf2), is the principal transcriptional regulator, that is central in mediating oxidative stress signal response. Having unequivocally established the relationship between type 2 diabetes mellitus (T2DM) and oxidative stress, the pivotal role of Nrf2/Keap1/ARE network, has taken the center stage as target for developing therapies towards maintaining the cellular redox environment. Several activators of Nrf2 are known to combat diabetes-induced ED and few are currently in clinical trials. Focusing on their therapeutic value in diabetes-induced ED, this review highlights some natural and synthetic molecules that are involved in the modulation of the Nrf2/Keap1/ARE network and its underlying molecular mechanisms in the regulation of ED. Further emphasis is also laid on the therapeutic benefits of directly up-regulating Nrf2-mediated antioxidant defences in regulating endothelial redox homeostasis for countering diabetes-induced ED.
- Published
- 2019
5. Association of single-nucleotide polymorphisms of the KEAP1 gene with the risk of various human diseases and its functional impact using in silico analysis
- Author
-
Umapathy Dhamodharan, Kunka Mohanram Ramkumar, Elango Bhakkiyalakshmi, Balashanmugam Ponjayanthi, and Dornadula Sireesh
- Subjects
0301 basic medicine ,Pharmacology ,Risk ,Kelch-Like ECH-Associated Protein 1 ,biology ,Chemistry ,In silico ,Signal transducing adaptor protein ,KEAP1 Gene ,Single-nucleotide polymorphism ,Null allele ,KEAP1 ,Polymorphism, Single Nucleotide ,Ubiquitin ligase ,Cell biology ,03 medical and health sciences ,030104 developmental biology ,Ubiquitin ,Protein Domains ,Mutation ,biology.protein ,Animals ,Humans ,Computer Simulation ,Genetic Predisposition to Disease - Abstract
Keap1, Kelch-like erythroid derived Cap ‘n’ collar homology (ECH) associated protein 1 is a highly redox-sensitive member of the BTB-Kelch substrate adaptor protein which acts as a major upstream regulator of Nrf2 (Nuclear factor erythroid 2-related factor 2) by Cul3 ubiquitin E3 ligase complex, leading to its proteasomal degradation. Oxidative and electrophilic stresses impair the structural integrity of Keap1-Cul3 ubiquitin E3 ligase complex resulting in the dissociation of Nrf2-Keap1 binding and nuclear accumulation of Nrf2. Studies on tissue-specific Keap1 null mutation have demonstrated the important roles of Keap1 mediated Nrf2 degradation. An increasing body of evidence suggests that loss of functional mutation in Keap1 arbitrates constitutive activation and expression of Nrf2 which in turn provokes the chemotherapeutic resistance in various diseases. The current review addresses the genetic aspects of KEAP1 including somatic mutations and in silico functional profiling of human disease-associated and polymorphic amino acid substitutions.
- Published
- 2018
6. The emerging role of redox-sensitive Nrf2–Keap1 pathway in diabetes
- Author
-
Dornadula Sireesh, Kunka Mohanram Ramkumar, P. Rajaguru, Ramasamy Paulmurugan, and Elango Bhakkiyalakshmi
- Subjects
Antioxidant ,NF-E2-Related Factor 2 ,medicine.medical_treatment ,Oxidative phosphorylation ,Pharmacology ,medicine.disease_cause ,Stress, Physiological ,Diabetes mellitus ,Diabetes Mellitus ,medicine ,Animals ,Humans ,Kelch-Like ECH-Associated Protein 1 ,Chemistry ,Mechanism (biology) ,Insulin ,Intracellular Signaling Peptides and Proteins ,medicine.disease ,KEAP1 ,Cell biology ,medicine.anatomical_structure ,Pancreas ,Oxidation-Reduction ,Oxidative stress ,Signal Transduction - Abstract
The pathogenic processes involving in the development of diabetes range from autoimmune destruction of pancreatic β-cells with consequent insulin deficiency to abnormalities that result in resistance to insulin action. The major contributing factor for excessive β-cell death includes oxidative stress-mediated mitochondrial damage, which creates an imbalance in redox homeostasis. Yet, β-cells have evolved adaptive mechanisms to endure a wide range of stress conditions to safeguard its potential functions. These include 'Nrf2/Keap1' pathway, a key cellular defense mechanism, to combat oxidative stress by regulating phase II detoxifying and antioxidant genes. During diabetes, redox imbalance provokes defective Nrf2-dependent signaling and compromise antioxidant capacity of the pancreas which turnout β-cells to become highly vulnerable against various insults. Hence, identification of small molecule activators of Nrf2/Keap1 pathway remains significant to enhance cellular defense to overcome the burden of oxidative stress related disturbances. This review summarizes the molecular mechanism behind Nrf2 activation and the impact of Nrf2 activators in diabetes and its complications.
- Published
- 2015
- Full Text
- View/download PDF
7. Antidiabetic effect of Gymnema montanum leaves: effect on lipid peroxidation induced oxidative stress in experimental diabetes
- Author
-
Rajendran Ananthan, Kunka Mohanram Ramkumar, M Latha, C Baskar, V NarmathaBai, and Leelavinothan Pari
- Subjects
Blood Glucose ,Male ,Antioxidant ,Free Radicals ,medicine.medical_treatment ,Ascorbic Acid ,Pharmacology ,Thiobarbituric Acid Reactive Substances ,Antioxidants ,Diabetes Mellitus, Experimental ,Lipid peroxidation ,Glibenclamide ,chemistry.chemical_compound ,Eating ,Glyburide ,medicine ,Animals ,Rats, Wistar ,Hypolipidemic Agents ,Gymnema ,biology ,Vitamin C ,Plant Extracts ,Vitamin E ,Body Weight ,Glutathione ,Hydrogen Peroxide ,biology.organism_classification ,Ascorbic acid ,Rats ,Plant Leaves ,Oxidative Stress ,chemistry ,Biochemistry ,Lipid Peroxidation ,medicine.drug ,Phytotherapy - Abstract
Gymnema montanum is widely used in ancient medicine for the ailment of various diseases. Oral administration of 200 mg kg(-1) (body weight) BW of the alcoholic extract of the leaf for 3 weeks resulted in a significant reduction in blood glucose and an increase in plasma insulin, whereas the effect of 50 and 100 mg kg(-1) BW was not significant. The alcoholic extract also resulted in decreased free radical formation in plasma of diabetic rats. Thus, this study shows that Gymnema montanum leaf extract (GLEt) possess antihyperglycemic and antiperoxidative effect. The decrease in lipid peroxides and increase in reduced glutathione (GSH), ascorbic acid (Vitamin C) and alpha-tocopherol (Vitamin E) clearly show the antioxidant properties of GLEt. The effect of GLEt was most prominently seen in the case of animals given 200 mg kg(-1) BW. In addition, the results suggest that GLEt was highly effective than the reference drug glibenclamide.
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.